239 related articles for article (PubMed ID: 29018051)
1. Phase III HEAT Study Adding Lyso-Thermosensitive Liposomal Doxorubicin to Radiofrequency Ablation in Patients with Unresectable Hepatocellular Carcinoma Lesions.
Tak WY; Lin SM; Wang Y; Zheng J; Vecchione A; Park SY; Chen MH; Wong S; Xu R; Peng CY; Chiou YY; Huang GT; Cai J; Abdullah BJJ; Lee JS; Lee JY; Choi JY; Gopez-Cervantes J; Sherman M; Finn RS; Omata M; O'Neal M; Makris L; Borys N; Poon R; Lencioni R
Clin Cancer Res; 2018 Jan; 24(1):73-83. PubMed ID: 29018051
[No Abstract] [Full Text] [Related]
2. Thermosensitive liposomal doxorubicin plus radiofrequency ablation increased tumor destruction and improved survival in patients with medium and large hepatocellular carcinoma: A randomized, double-blinded, dummy-controlled clinical trial in a single center.
Yang W; Lee JC; Chen MH; Zhang ZY; Bai XM; Yin SS; Cao K; Wang S; Wu W; Yan K
J Cancer Res Ther; 2019; 15(4):773-783. PubMed ID: 31436231
[TBL] [Abstract][Full Text] [Related]
3. Radiofrequency Ablation Duration per Tumor Volume May Correlate with Overall Survival in Solitary Hepatocellular Carcinoma Patients Treated with Radiofrequency Ablation Plus Lyso-Thermosensitive Liposomal Doxorubicin.
Celik H; Wakim P; Pritchard WF; Castro M; Leonard S; Karanian JW; Dewhirst MW; Lencioni R; Wood BJ
J Vasc Interv Radiol; 2019 Dec; 30(12):1908-1914. PubMed ID: 31409568
[TBL] [Abstract][Full Text] [Related]
4. Imaging Features of Radiofrequency Ablation with Heat-Deployed Liposomal Doxorubicin in Hepatic Tumors.
Hong CW; Chow L; Turkbey EB; Lencioni R; Libutti SK; Wood BJ
Cardiovasc Intervent Radiol; 2016 Mar; 39(3):409-16. PubMed ID: 26228246
[TBL] [Abstract][Full Text] [Related]
5. Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer.
Poon RT; Borys N
Future Oncol; 2011 Aug; 7(8):937-45. PubMed ID: 21823888
[TBL] [Abstract][Full Text] [Related]
6. RFA plus lyso-thermosensitive liposomal doxorubicin: in search of the optimal approach to cure intermediate-size hepatocellular carcinoma.
Lencioni R; Cioni D
Hepat Oncol; 2016 Aug; 3(3):193-200. PubMed ID: 30191041
[TBL] [Abstract][Full Text] [Related]
7. Lyso-thermosensitive liposomal doxorubicin: a novel approach to enhance efficacy of thermal ablation of liver cancer.
Poon RT; Borys N
Expert Opin Pharmacother; 2009 Feb; 10(2):333-43. PubMed ID: 19236203
[TBL] [Abstract][Full Text] [Related]
8. Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model.
Swenson CE; Haemmerich D; Maul DH; Knox B; Ehrhart N; Reed RA
PLoS One; 2015; 10(10):e0139752. PubMed ID: 26431204
[TBL] [Abstract][Full Text] [Related]
9. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma.
Song MJ; Bae SH; Lee JS; Lee SW; Song DS; You CR; Choi JY; Yoon SK
Korean J Intern Med; 2016 Mar; 31(2):242-52. PubMed ID: 26874512
[TBL] [Abstract][Full Text] [Related]
10. Two phase I dose-escalation/pharmacokinetics studies of low temperature liposomal doxorubicin (LTLD) and mild local hyperthermia in heavily pretreated patients with local regionally recurrent breast cancer.
Zagar TM; Vujaskovic Z; Formenti S; Rugo H; Muggia F; O'Connor B; Myerson R; Stauffer P; Hsu IC; Diederich C; Straube W; Boss MK; Boico A; Craciunescu O; Maccarini P; Needham D; Borys N; Blackwell KL; Dewhirst MW
Int J Hyperthermia; 2014 Aug; 30(5):285-94. PubMed ID: 25144817
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of Radiofrequency Ablation
Martin AN; Wilkins LR; Das D; Johnston LE; Bauer TW; Adams RB; Zaydfudim VM
Am Surg; 2019 Feb; 85(2):150-155. PubMed ID: 30819290
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies.
Wood BJ; Poon RT; Locklin JK; Dreher MR; Ng KK; Eugeni M; Seidel G; Dromi S; Neeman Z; Kolf M; Black CD; Prabhakar R; Libutti SK
J Vasc Interv Radiol; 2012 Feb; 23(2):248-55.e7. PubMed ID: 22178041
[TBL] [Abstract][Full Text] [Related]
13. Safety and feasibility of ultrasound-triggered targeted drug delivery of doxorubicin from thermosensitive liposomes in liver tumours (TARDOX): a single-centre, open-label, phase 1 trial.
Lyon PC; Gray MD; Mannaris C; Folkes LK; Stratford M; Campo L; Chung DYF; Scott S; Anderson M; Goldin R; Carlisle R; Wu F; Middleton MR; Gleeson FV; Coussios CC
Lancet Oncol; 2018 Aug; 19(8):1027-1039. PubMed ID: 30001990
[TBL] [Abstract][Full Text] [Related]
14. Comparison of transarterial chemoembolization with radiofrequency ablation for unresectable Barcelona Clinic Liver Cancer stage 0/A hepatocellular carcinoma: a propensity score matching.
Chen RX; Gan YH; Ge NL; Chen Y; Ma H; Wang Y; Zhang BH; Wang YH; Ye SL; Luo JF; Ren ZG
J Gastroenterol Hepatol; 2016 Feb; 31(2):442-9. PubMed ID: 26259976
[TBL] [Abstract][Full Text] [Related]
15. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer.
Mikhail AS; Negussie AH; Pritchard WF; Haemmerich D; Woods D; Bakhutashvili I; Esparza-Trujillo J; Brancato SJ; Karanian J; Agarwal PK; Wood BJ
Int J Hyperthermia; 2017 Nov; 33(7):733-740. PubMed ID: 28540814
[TBL] [Abstract][Full Text] [Related]
16. Microwave vs radiofrequency ablation for hepatocellular carcinoma within the Milan criteria: a propensity score analysis.
Liu W; Zheng Y; He W; Zou R; Qiu J; Shen J; Yang Z; Zhang Y; Wang C; Wang Y; Zuo D; Li B; Yuan Y
Aliment Pharmacol Ther; 2018 Sep; 48(6):671-681. PubMed ID: 30063081
[TBL] [Abstract][Full Text] [Related]
17. Iodine-125 Brachytherapy Prophylaxis after Radiofrequency Ablation Cannot Benefit Patients in High Risk of Locoregional Hepatocellular Carcinoma Recurrence.
Tu JF; Ding YH; Chen L; Ying XH; Zhang DK; Wu FZ; Zhao ZW; Ji JS; Zhang WG; Zou H
Sci Rep; 2017 Jun; 7(1):3689. PubMed ID: 28623296
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Transarterial Chemoembolization Combined with Radiofrequency Ablation Therapy
Yi PS; Huang M; Zhang M; Xu L; Xu MQ
Am Surg; 2018 Feb; 84(2):282-288. PubMed ID: 29580359
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Feng X; Xu R; Du X; Dou K; Qin X; Xu J; Jia W; Wang Z; Zhao H; Yang S; Guo C; Liu T; Ma K
Am J Gastroenterol; 2014 Dec; 109(12):1891-9. PubMed ID: 25403366
[TBL] [Abstract][Full Text] [Related]
20. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization.
Green TJ; Rochon PJ; Chang S; Ray CE; Winston H; Ruef R; Kreidler SM; Glueck DH; Shulman BC; Brown AC; Durham J
J Vasc Interv Radiol; 2013 Nov; 24(11):1613-22. PubMed ID: 24060436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
